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AbstrAct
Objective Due to long lag time between infection/
cancer diagnoses human papillomavirus (HPV) 
vaccination programs will deliver vaccine efficacy 
(VE) estimates against cancer end-points late. Cancer 
registry follow-up of population-based, randomised trial 
cohorts of vaccinated and unvaccinated women was 
undertaken for the estimation of VE against cervical 
intraepithelial neoplasia grade three and invasive cancer 
(CIN3+).
Methods We report interim results with 98 561 person 
years of Finnish Cancer Registry -based follow-up of 
individually and/or cluster randomised cohorts of HPV-
16/18 vaccinated and unvaccinated adolescent women 
enrolled in June 2003/2005, and between May 2004 
and April 2005, respectively. The cohorts comprised 
15 627 18- to 19-year-old unvaccinated women 
(NCT01393470), and 2 401 and 64 16- to 17-year-old 
HPV-16/18 vaccinated women participating the PATRICIA 
(NCT00122681) and HPV-012 (NCT00169494) trials, 
respectively. The age-aligned passive follow-up started 
6 months after the clinical trials’ end.
results During the follow-up of 4.5 to 10 years 
post enrolment we identified 75 cases of cervical 
intraepithelial neoplasia grade 3 (CIN3) and 4 cases 
of invasive cervical cancer (ICC) in the unvaccinated 
cohort, and 4 CIN3 cases in the HPV-16/18 vaccinated 
women. Diagnostic blocks were available for HPV typing 
from 87% of the cases. CIN3+ lesions were detectable 
in 54 cases. HPV16 was found in 26 of 50 unvaccinated 
CIN3+ cases, and in 3 CIN3+ cases in the HPV-16/18 
vaccinated women. The latter were all baseline positive 
for cervical HPV16 DNA. Baseline data was not available 
for the unvaccinated women. Intention-to-treat VE 
against any CIN3+ was 66% (95% CI 8, 88).
conclusions Ten years post vaccination the AS04-
adjuvanted HPV-16/18 vaccine shows continued efficacy 
against CIN3+ irrespectively of HPV type. Vaccine efficacy 
was not observed in baseline HPV16 DNA positive subjects.
trial registration number NCT01393470.
IntrOductIOn
High-risk (hr) human papillomaviruses 
(HPVs) cause up to 9% and 1% of cancers 
in females and males.1 Bivalent, quadri-
valent and nonavalent vaccines against 
HPV types 16/18, 6/11/16/18, and 
6/11/16/18/31/33/45/52/58, respec-
tively, have an acceptable safety profile and 
are highly efficacious against a number 
of infections with hrHPVs and associated 
precancers.2–6 Proof of vaccine efficacy (VE) 
against HPV-associated cancers is, however, 
not easy to reach due to the long lag time 
between exposure to the virus and diagnosis 
of the associated cancer. This phenomenon 
is not uncommon, and has for instance 
hindered the determination of VE against 
hepatitis B virus (HBV) associated hepatocel-
lular carcinoma, since the time lag between 
virus exposure and diagnosis of carcinoma is 
15 to 25.7 8
Proving the concept of vaccine induced 
protection against (one of) the major 
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Research
strengths and limitations of this study
 ► Country-wide cancer registry follow-up of sizeable 
randomised cohorts of HPV vaccinated and 
unvaccinated women for 100.000 person years (up 
to10 years post vaccination) provides most reliable 
vaccine efficacy estimates against cancerous end- 
points.
 ► Retrieval of most diagnostic histopathological blocks 
and state-of-science identification of the causal HPV 
type in the lesion enable identification of HPV type-
specific vaccine efficacy estimates.
 ► The per protocol defined interim analysis has limited 
statistical power.
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HPV-associated cancers, i.e., in situ and invasive cervical 
carcinoma is not only of conceptual but also of practical 
importance. It would guarantee the impact of primary 
cancer prevention via prophylactic HPV vaccination, 
guide targeting this prophylaxis, and provide the scien-
tific basis for understanding how and when such proof 
will be available for other HPV-associated cancers such 
as non-cervical anogenital cancers, and head and neck 
cancers.
Our objective is to determine VE against cervical 
cancer. To accomplish this we identify invasive cervical 
cancer (ICC) and intraepithelial neoplasia grade 3 
(CIN3+) incidence in passive, population-based cancer 
registry follow-up of a randomised clinical HPV vaccine 
trial cohort (PATRICIA),4 and a cluster-randomised 
control cohort enrolled in 2003-2005.9–11 The follow-up 
of originally adolescent females has previously proven 
to be feasible.12 With the observed CIN3+ incidence of 
93.4/100 000 in the control cohort,12 which equals that 
of the Finnish female population of similar age 99.5/100 
000,12 it is well powered to verify 65% VE against CIN3+ 
and ICC, 10 and 15 years post vaccination, respectively.9–12 
We report interim results on the efficacy of the bivalent 
HPV16/18 vaccine against overall and HPV type-specific 
CIN3+ end-points.
MethOds
Study design and Ethics Our cluster-randomised 
follow-up study involves separate birth cohorts of clinical 
trial participants4 12 13 aged 16–17 years and unvaccinated 
non-participants9 10 aged 18–19 years assigned according 
to the start of PATRICIA14 trial in May 2004 by ML (the 
principal investigator for phase III HPV vaccination 
trials in Finland). The former were also individually 
randomised.13 The trials, establishing the unvaccinated 
control cohort and their Finnish Cancer Registry (FCR) 
–based follow-up were approved by the Finnish National 
Ethical Review Board (TUKIJA: 1174/2004 and 
1153/2003), respectively
The study involved consecutive recruitment of adjacent, 
partially overlapping birth cohorts subjected to i) HPV 
vaccination and 4 years of clinical follow-up including 
cervical cytological sampling (birth cohorts Q2/1986 to 
Q1/1988), or ii) 4 years of clinical follow-up including 
cervical cytological sampling (birth cohorts Q2/1986 to 
Q1/1988), and iii) unvaccinated and no intervention 
(birth cohorts Q3/1984 to Q2/1985, and birth cohorts 
Q3/1985 to Q2/1987). The intervention measured was 
vaccination with the AS04-adjuvanted HPV-16/18 vaccine 
against no vaccination with the end-point: cervical 
intraepithelial neoplasia grade three or invasive cervical 
cancer (CIN3+). The end-points were histopatholog-
ically diagnosed 0–4 years post vaccination (during the 
active follow-up), 4–4.5 years post vaccination (during 
the intermittent period between the active follow-up and 
the passive follow-up), or 4.5–10 years post vaccination 
(during the passive follow-up).
Patient involvement Patients (with cervical neoplasia / 
condyloma) were not involved in the design of this study 
in 2000. A study on the feasibility of population-based 
enrolment was done in 1998.14
Enrolment Starting in May 2004 originally all 24 
046 (Q2/1986-Q1/1988 born) 16–17 year old Finnish 
females resident in 17 trial communities were sent invi-
tations to participate to the PATRICIA trial (HPV-008, 
NCT00122681) on the immunogenicity, safety and effi-
cacy of the AS04-adjuvanted HPV-16/18 vaccine against 
HPV16/18 positive CIN2+ (figure 1). By June 2005 a 
total of 4 808 women participated. They were randomly 
assigned to HPV-16/18 or hepatitis A-virus (HAV) vaccina-
tion in 1:1 ratio to receive three doses of the HPV-16/18 
vaccine or the HAV vaccine at months 0, 1 and 6, followed 
by seven active follow-up visits with 6 month interval up to 
4 years.4 13 In addition, 64 16–17 year olds received 3 doses 
of the HPV-16/18 vaccine by May 2005 in a concomitant 
HPV-012 trial which ended 4 years later.15
Following the end of the active follow-up in May 2009, 
approximately 50% of the HAV-vaccine recipients chose 
HPV-16/18 cross-vaccination during 2009–2010. HrHPV 
DNA positives at the last PATRICIA trial visit (215 from 
the HPV-16/18 cohort and 318 from the HAV cohort) 
continued active clinical follow-up (HPV-052 study 
protocol) for approximately 1.9 years after the end of the 
PATRICIA trial. They had annual HPV testing cytology 
until HPV DNA negative or exit colposcopy after 4 years.
An unvaccinated control cohort from entire adjacent 
birth cohorts of 18–19 year olds was recruited inviting 30 
947 and 58 996 in May/June 2003/5 by the Finnish Popu-
lation Register Centre as described (NCT01393470).9–11 
All PATRICIA4 13 and earlier Future12 trial participants 
were excluded from the control cohort. There were no 
healthcare interventions targeted to the control cohort.
Follow-up Both the vaccinated and unvaccinated 
control cohorts responded at the age of 22–23 years to 
a questionnaire on life habits with special emphasis on 
sexual health, that is, at the beginning of the passive 
registry-based follow-up.16 17 Opportunistic vaccination 
by Gardasil or Cervarix vaccines after their licensures in 
2006 and 2007 was considered based on questionnaires in 
2007 and 2009, and among the vaccinated PATRICIA and 
HPV-012 trial cohorts in 2010. In addition, vital status and 
emigration were updated until the end of 2014.
Invitations to cervical screening were sent to all study 
participants at the age of 25 years, also in communities 
which organise the screening from age 30 onwards. With 
over-lapping time-windows of 5.5 years we age-aligned the 
passive follow-up for the different birth cohorts.12
The study outcomes were CIN3+ lesions diagnosed 
during the passive follow-up. According to local stan-
dard of care, women with cytological abnormalities 
were referred to colposcopy biopsy for histopathological 
diagnosis within a 6 month period following cytology.18 
Thus, the passive, Finnish Cancer Registry (FCR) -based 
follow-up was started 6 months after the end of active 
clinical follow-up of the PATRICIA (and 052) trial and 
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Figure 1 Consort diagram with relevant invitation, enrolment and exclusion criteria/steps.*Due to migration not eligible to 
Finnish Cancer Registry follow-up.
Table 1 Sample size and power calculations for a registry-based follow-up study on the efficacy of human papillomavirus 
(HPV) type 16/18 vaccine against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+).  (A) Required 
sample sizes for the cancer-registry follow-up phase III trial cohorts assuming 90% vaccine efficacy against CIN3+ (statistical 
power: 1-β=80%, α=0.05) and 10 years of follow-up. (B) Statistical power with actuarial*† sample sizes for the cancer-registry 
follow-up of phase III trial cohorts assuming 50%, 70% and 90% HPV vaccine efficacy (VE) against CIN3+ 
Cumulative incidence % Category Design 1:3 Design 1:4
0.2 HPV vaccinated/unvaccinated 3 990/11 970 3 880/15 520
0.4 HPV vaccinated/unvaccinated 1 773/5 319 1 685/6 740
0.6 HPV vaccinated/unvaccinated 936/2 808 889/3 556
0.8 HPV vaccinated/unvaccinated 795/2 385 755/3 220
1.2 HPV vaccinated/unvaccinated 495/1 485 470/1 880
Cumulative incidence % Category VE 50% VE 70% VE 90%
0.3 HPV vaccinated*/unvaccinated† 0.203  0.441 0.825
0.6 HPV vaccinated*/unvaccinated† 0.447  0.847 0.998
0.9 HPV vaccinated*/unvaccinated† 0.657 0.973 1.000
1.2 HPV vaccinated*/unvaccinated† 0.805 0.996 1.0000
*2465 HPV-16/18 vaccinated and †15 627 unvaccinated women followed up for up to 10 years post vaccination by a population-based 
cancer registry
012 trials. For the control cohort the passive follow-up 
was age-aligned by a comparable time-period.12 Based 
on age-specific incidence of CIN3+ in the Finnish female 
population (www. cancer. fi) the enrolled cohorts of 
HPV-16/18 vaccinated women and control women exceed 
the numbers required for at least 80% power to iden-
tify statistically significant 65% vaccine efficacy against 
CIN3+.9 10 An interim analysis for CIN3+ was planned to 
take place after 5 years of passive follow-up, and the final 
analysis for ICC after 10 years of passive follow-up.
The FCR is population-based and receives cancer notifi-
cations from the entire country with 100% coverage, and 
80% coverage for CIN3 (www. cancer. fi). Individually, the 
passive follow-up of the different cohorts extended until 
10 years post vaccination or from the receipt of informed 
consent (unvaccinated women) up to the end of 2014.
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Table 2 Demographic characteristics of the cohorts subjected to Finnish Cancer Registry follow-up.
Category
HPV-16/18 vaccinated
(n = 2 472)
HAV-vaccinated 
(n=2 399) 
Unvaccinated 
(n=15 627) 
Age at enrolment 16–17  years 16–17  years 18–19  years
Age at passive follow-up 22–28  years 22–28  years 22–28  years
Response rate* 1 107 (46.5%) 1 010 (42.1%) 7 118 (45.5%)
Sexual debut (mean age) 15.8  years 16.0  years 16.4  years
No. of life-time partners
  0 37 (3.3%) 32 (3.2%) 400 (5.6%)
  1 143 (12.9%) 146 (14.5%) 1 335 (18.8%)
  2 131 (11.8%) 114 (11.3%) 750 (10.5%)
  3–9 511 (46.2%) 458 (45.3%) 3 023 (42.4%)
  10 or more 284 (25.7%) 257 (25.4%) 1 588 (22.3%)
No. of partners in the past
12 months
  0 531 (49.8%) 507 (50.2%) 3 848 (54.1%)
  1 237 (21.4%) 230 (22.8%) 1 365 (19.2%)
  2 111 (10.1%) 92 (9.1%) 580 (8.1%)
three or more 170 (15.4%) 145 (14.4%) 914 (12.8%)
Use of contraception
BCP (ever) 1 028 (92.9%) 920 (91.1%) 6 017 (84.5%)
Condom†
  use 298 (26.9%) 261 (25.8%) 2 004 (28.2%)
  no use 787 (71.1%) 728 (72.1%) 4 977 (69.5%)
No contraception 1 (0.1%) 5 (0.5%) 56 (0.8%)
*returned questionnaires at the age of 22–23 years when the passive follow-up was started
†last year
Table 3 Incidence rate (/100 000 women years) of cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+) in 
cluster-randomised cohorts of 16- to 17-year-old HPV-16/18 vaccine recipients, and unvaccinated originally 18- to 19 year old 
women. Passive follow- up was by the population-based Finnish Cancer Registry up to 10 years post vaccination.
End point of the 
follow-up
Vaccine Control
N  Person yrs n Rate* N Person yrs  n Rate*
FCR registered CIN3+ diagnoses
  Active 2472     10 199 – – 15 665   62 628 – –
  Intermittent 2 466    1 232 1 81 15 634 7 815 – –
  Passive 2 465   12 561 4 32 15 627    85 328 79 93
KI re-reviewed CIN3+ diagnoses
  Intermittent 2 466    1 232 1 81 15 634   7 815 – –
  Passive 2 465    12 561 3 24 15 627    85 328 50 59
Active (0–4 years), Intermittent (4–4.5 years), Passive (4.5–10 years)
*incidence/100 000 women years
Following Finnish national ethical committee clear-
ances in 2003 and 2004, registers of HPV-16/18 vaccinated 
and unvaccinated cohorts were established and have 
since been maintained at the University of Tampere.9 10 
Permission to link these registers with the FCR for the 
identification new cancer cases until 2024 was obtained 
from the Finnish Institute for Health & Welfare in 2004.
For the interim analysis the age-aligned HPV-16/18 
vaccine (n=2 465) and the unvaccinated control 
cohort (n=15 627) were linked using personal identi-
fiers with the FCR to determine the incidence (per 100 
000 person years) of CIN3 and ICC (CIN3+) during 
the overlapping 5.5 year follow-up periods of passive 
follow-up.
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Table 4 Characteristics of 5 CIN3 cases identified among the 2 466 recipients of the HPV-16/18 vaccine in the Finnish Cancer 
Registry –based passive long-term follow-up of the clinical trial participants between 4.5 and 10 years post vaccination.
Age at 
enrolment
Baseline cervical HPV 
DNA status
 Number of doses  
received  in 2004-20 Date of diagnosis
d-point (CIN3) HPV 
DNA status
HPV-052 
participant
16  years HPV16 three doses Sep 2010 HPV16 no
17  years HPV16 three doses May 2012 HPV16  no
17  years HPV16 three doses Mar 2013 HPV16  no
16  years HPV31 three doses Apr 2013 n.a.  yes*
17  years HPV16 three doses Mar 2012 HPV16  yes†
*One HPV DNA test after the end of the PATRICIA trial 3.5 years before the CIN3+ diagnosis
†CIN3+ diagnosis made before start of the passive follow-up
Histopathological block retrieval and re-analysis Diag-
nostic, formalin-fixed histopathological blocks were 
identified by the permission of Valvira, a department of 
the Finnish Ministry of Health and Social Welfare. An 
experienced pathologist confirmed that the retrieved 
archival diagnostic block contained a CIN3+ lesion. All 
eligible blocks were sectioned according to a PCR-proof 
manner as described.19 Extraction, amplification and 
typing of the lesional HPV DNA was performed as previ-
ously described.19
Statistic analysis Vaccine efficacy (VE) was calculated 
as 1 - incidence rate in vaccinated / incidence rate in 
unvacctinated following the intention-to-treat (ITT) prin-
ciple including all individuals regardless of baseline HPV 
status receiving at least one HPV-16/18 vaccine dose in 
the arm of HPV vaccinated using statistical software SAS 
9.4 software (SAS Institute, Cary, NC, USA) according to 
Ewell20 and Chan.21 The 95% confidence intervals were 
based on exact binomial distribution of number of vacci-
nated cases conditional on total number of cases.20 21
results
Between May 2004 and June 2005 a total of 4 808 
16–17 year-old Finnish women participated the PATRICIA 
(HPV-008) trial (figure 1). Concomitantly, 64 16–17 year 
old Finnish females received the AS04-adjuvanted 
HPV-16/18 vaccine in an HPV-012 immunogenicity 
trial. In May to June 2003 and 2005 respectively 6 790 
and 10 220 18–19 year old non-HPV vaccinated women 
responded to a health questionnaire and consented 
to the passive registry-based follow-up. Only the 15 627 
women who were willing to participate in an HPV vaccina-
tion trial provided that they were of appropriate age, and 
retained their consent for 10 years were eligible to the 
control cohort of unvaccinated women (figure 1). The 
actuarial numbers of vaccinated and unvaccinated study 
participants followed up for 10 years yielded sufficient 
statistical power for the main study outcome: VE against 
overall CIN3+ (table 1).
The demographics of the HPV-16/18 vaccine and 
control cohorts did not differ except for the birth cohort 
(table 2). The proportions of ever users of oral contra-
ceptives and the number of sexual partners were slightly 
higher, and the time of sexual debut was slightly lower 
in the vaccinated women as compared with the unvacci-
nated women. The sizeable cohorts of unvaccinated and 
HPV-16/18 vaccinated women for ITT-analysis resulted 
in 98 561 years of follow-up. Mixture of cross-vaccination 
and continuation of active follow-up in the HAV vaccine 
arm precluded it from the passive long-term follow-up.
Re-review of all the 84 CIN3+ cases was performed 
in 87 percent of the cases. The presence of CIN3+ was 
confirmed in 74 percent of the diagnostic blocks avail-
able (table 3). Three of the 4 CIN3 cases identified 
during the passive follow-up among the HPV-16/18 vacci-
nated individuals could be confirmed in the re-review. 
All were baseline (pre-vaccination) positive for cervical 
HPV16 DNA, and HPV16 DNA was identified also in the 
diagnostic blocks containing the CIN3 lesion (table 4). 
The fourth CIN3 case was baseline HPV31 DNA positive 
but no diagnostic block was available. One CIN3 case was 
diagnosed  during the prolonged follow-up in the 052 
study.
All the CIN3+ cases were found in the FCR follow-up 
between 4.5 to 10 years post vaccination. Identifica-
tion of 4 and 79 cases yielded overall CIN3+ incidence 
rates of 32/100 000 and 93/100 000 women years in 
the HPV-16/18 vaccinated cohort and the unvaccinated 
cohort, respectively. This resulted in 66% (95%CI 8, 
88) overall VE against CIN3+, irrespectively of HPV 
type (table 4). For the re-reviewed material the corre-
sponding overall VE against CIN3+ was 59% (95%CI 
−26, 85).
In the two cohorts, HPV16 was found in all the three 
HPV-16/18 vaccinated CIN3 cases and in 52% (26) of the 
unvaccinated CIN3+ cases that were available and eligible 
for HPV DNA typing (table 5). VEs against HPV16 or 
HPV16/18 associated CIN3+ were low (table 5). The VE 
estimate against other than HPV16 clade A9 HPV type, 
including 31/33/52/58, associated CIN3+ increased from 
53% to 100% when CIN3+ lesions with HPV16 co-infec-
tion were excluded from the analysis (table 5). Numbers 
for clade A7 or other non clade A9 HPV types were small.
There were no healthcare interventions targeted to 
the control cohort, and the cancer-registry follow-up was 
passive. No harm was caused in this study.
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dIscussIOn
Ten years post vaccination we found statistically signifi-
cant VE of 66% for the HPV-16/18 vaccine against any 
CIN3+ in passive cancer registry -based follow-up of our 
population-based cohorts comprising more than 18 000 
originally 16- to 19 year old women.
Our interim ITT estimates of VE against any CIN3+ are 
in line with what we reported about the 4 year follow-up 
of the total vaccinated cohort (TVC) from the PATRICIA 
trial: VE was 45.3%.4 With the close to 100.000 follow-up 
years and FCR –based follow-up, our 80% power, 0.6% 
cumulative CIN3+ incidence and 70% VE assumptions9 10 
were conservative. Retrieval and review of the histo-
pathological blocks were important quality control steps 
for the HPV typing which, even if informative, was not 
always possible. It also diversified the end-points yielding 
very wide confidence intervals. However, even with the 
reduced number of HPV typed cases the overall CIN3+ 
VE estimate of 59% (CI included 0) was comparable with 
the above Finnish Cancer Registry information-based 
estimate. Unfortunately, the lack of baseline data for 
the unvaccinated cohort precluded the TVC-naive (ie, 
baseline HPV negative) type of analyses which earlier 
demonstrated a very high (93.2%) VE against any CIN3, 
irrespectively of HPV type in the PATRICIA trial 4 years 
post vaccination.4
One limitation was that some HPV-16/18 vaccinated 
women (8.3%) also participated in the HPV-052 study, 
the effects of which may have been contradictory. In one 
of these women annual HPV DNA screening may have 
led to an earlier detection of the CIN3 lesions, identi-
fied in the FCR follow-up, due to the high sensitivity of 
HPV DNA screening compared with conventional oppor-
tunistic cytology.22 On the other hand, removal of an 
earlier CIN lesion in an HPV-052 participant could theo-
retically have led to excision of a lesion that might have 
surfaced as CIN3+ in the FCR follow-up. ITT analysis of 
the entire cohorts of HPV-16/18 vaccinated and unvacci-
nated women participating in the passive follow-up does 
not allow distinguishing between these two alternatives 
but is a conservative approach. Most importantly for 
the validity of the ongoing long-term follow-up, all our 
vaccinated and unvaccinated study subjects were invited 
to organised cytological screening visits at the age of 25 
years. Moreover, opportunistic HPV vaccination among 
the unvaccinated controls following the licensure of the 
quadrivalent Gardasil and bivalent Cervarix HPV vaccines 
in 2006 and 2007, respectively has been negligible (data 
not shown).
We found only a relatively low long-term vaccine effi-
cacy against HPV-16/18 positive CIN3+. This was because 
several baseline, pre-vaccination HPV16 positive vaccine 
recipients, developed HPV16 positive CIN3 during the 
10 years of post vaccination follow-up. The HPV-16/18 
AS04-adjuvanted vaccine,6 does not protect against the 
HPV16 positive CIN3+ if viral infection already exists and 
persistent HPV16 infection has been established. The low 
efficacy observed in the PATRICIA trial among baseline 
positives already pointed to this direction.23 Vaccination 
of adult women24 of whom up to 30+% already have been 
exposed to hrHPV infection may not be the most effective 
HPV vaccination strategy.
In conclusion, ten years post vaccination the AS04-ad-
juvanted HPV-16/18 vaccine shows continued efficacy 
against CIN3+ irrespectively of HPV type. Our results 
also suggest that the wide cross-protective efficacy of 
the HPV-16/18 vaccine reported in clinical trials against 
HPV types 31/33/454 5 is true for the associated CIN3+ 
end-point in the long-term context. It is warranted to 
continue the long-term follow-up of the HPV vaccina-
tion trial cohorts to more accurate HPV type-specific 
CIN3+ end-points and all HPV-associated invasive cancer 
end-points.
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